Article Text

Download PDFPDF
311 Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment
  1. Eun Bi Jang1,
  2. Yoon Sun Kook1,
  3. Soo Jin Jung1,
  4. A Jin Lee1,
  5. Kyeong A So1,
  6. Sun Joo Lee1,
  7. Ji Young Lee1,
  8. Tae Jin Kim1,
  9. Soon-Beom Kang2 and
  10. Seung-Hyuk Shim1
  1. 1Konkuk University School of Medicine, Seoul, South Korea
  2. 2Hosan Women Hospital, Seoul, South Korea


Introduction/Background This study aims to assess recurrence risk factors in patients with early-stage endometrioid endometrial cancer who have achieved complete remission (CR) through fertility-sparing hormonal treatment (FST).

Methodology We retrospectively analyzed patients who received FST for presumed stage IA, grade 1 endometrioid endometrial cancer at two institutions. Medroxyprogesterone and levonorgestrel-releasing intrauterine devices were used concurrently for treatment. Cox regression analysis was used to identify the clinicopathological variables for recurrence-free survival (RFS) following CR.

Results Among 180 patients with presumed stage IA, grade 1 endometrioid endometrial cancer who received FST, (n=144, 80.0%) had complete remission. The median time to achieve CR and the median duration of FST was 10 months (range 1–34) and 14 months (range 3–49), respectively. During the median follow-up period of 43.5 months (range 4–143), (n=85, 59.0%) patients had recurrence with median RFS of 13 months (range 1–123) after CR. On multivariable analysis, age (HR 1.062, 95% CI 1.016 to 1.110; P<0.05), and pregnancy (HR 0.185, 95% CI 0.085 to 0.405; P<0.05) were significantly associated with RFS.

Conclusion Older age, non-pregnancy might be risk factors for early failure of first-line FST. Therefore, patients with these conditions should receive close and frequent follow-up, including imaging and histology examinations, to detect recurrence after complete remission.

Disclosures COI: none.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.